The 36-month beta value for BBIO is at 1.11. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 6 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BBIO is 160.74M, and currently, shorts hold a 13.68% of that float. The average trading volume for BBIO on June 18, 2025 was 2.87M shares.
BBIO) stock’s latest price update
BridgeBio Pharma Inc (NASDAQ: BBIO) has seen a decline in its stock price by -2.60 in relation to its previous close of 41.14. However, the company has experienced a -0.05% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-04 that BridgeBio’s Attruby launch crushed expectations, with Q1 revenue triple analyst estimates, driven by higher-than-expected conversion rates and minimal free trial usage. Competitive threats from Amvuttra appear overstated, as Attruby script declines were minor and BridgeBio management remains confident in market positioning and pricing. My updated model projects 2025 revenues of $728 million, far above consensus, and sees potential for nearly $1 billion in 2026 from existing patients alone.
BBIO’s Market Performance
BridgeBio Pharma Inc (BBIO) has experienced a -0.05% fall in stock performance for the past week, with a 18.41% rise in the past month, and a 24.48% rise in the past quarter. The volatility ratio for the week is 2.52%, and the volatility levels for the past 30 days are at 2.31% for BBIO. The simple moving average for the past 20 days is 9.39% for BBIO’s stock, with a 29.59% simple moving average for the past 200 days.
Analysts’ Opinion of BBIO
Many brokerage firms have already submitted their reports for BBIO stocks, with Wolfe Research repeating the rating for BBIO by listing it as a “Outperform.” The predicted price for BBIO in the upcoming period, according to Wolfe Research is $49 based on the research report published on June 17, 2025 of the current year 2025.
Redburn Atlantic, on the other hand, stated in their research note that they expect to see BBIO reach a price target of $50. The rating they have provided for BBIO stocks is “Buy” according to the report published on March 31st, 2025.
BBIO Trading at 12.81% from the 50-Day Moving Average
After a stumble in the market that brought BBIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.11% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BBIO starting from Valantine Hannah, who sale 4,292 shares at the price of $40.00 back on Jun 10 ’25. After this action, Valantine Hannah now owns 1,764 shares of BridgeBio Pharma Inc, valued at $171,680 using the latest closing price.
HANNAH A VALANTINE, the Director of BridgeBio Pharma Inc, proposed sale 4,292 shares at $40.00 during a trade that took place back on Jun 10 ’25, which means that HANNAH A VALANTINE is holding shares at $171,680 based on the most recent closing price.
Stock Fundamentals for BBIO
Current profitability levels for the company are sitting at:
- -5.48 for the present operating margin
- 0.97 for the gross margin
The net margin for BridgeBio Pharma Inc stands at -5.24. The total capital return value is set at -0.96.
Based on BridgeBio Pharma Inc (BBIO), the company’s capital structure generated -0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -49.43. The debt to equity ratio resting at -0.01. The interest coverage ratio of the stock is -5.91.
Currently, EBITDA for the company is -436.83 million with net debt to EBITDA at 0.96. When we switch over and look at the enterprise to sales, we see a ratio of 55.55. The receivables turnover for the company is 1.11for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.57.
Conclusion
In conclusion, BridgeBio Pharma Inc (BBIO) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
